Antifungal prophylaxis for severely neutropenic chemotherapy recipients: A meta-analysis of randomized-controlled clinical trials

Cancer

Volumn 94, Issue 12, 2002, Pages 3230-3246

  Bow, Eric J ^a,e   Laverdière, Michel ^b   Lussier, Nathalie ^b   Rotstein, Coleman ^c   Cheang, Mary S ^a   Ioannou, Stratis ^d  

^a UNIVERSITY OF MANITOBA   (Canada)

^b L'Hôpital Maisonneuve Rosemont ^*  (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d PFIZER INC   (United States)

^e HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Amphotericin B; Antifungal prophylaxis; Azoles; Meta analysis; Neutropenia; Randomized controlled trials

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CLOTRIMAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORBIDITY; MORTALITY; MYCOSIS; NEUTROPENIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS;

ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYCOSES; NEOPLASMS; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS;

EID: 0037096886     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10610     Document Type: Article

References (119)

1. Invasive fungal infection in patients receiving intensive cytotoxic therapy for cancer
2. Infection risk and cancer chemotherapy: The impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies
3. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: The pathogenetic role of the antileukemic regimen
4. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation
5. Control of construction-associated nosocomial aspergillosis in an antiquated hematology unit
6. Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in acute leukemia
7. Infection prevendon in acute nonlymphocytic leukemia-laminar air flow room reverse isolation with oral nonabsorbable antibiotic prophylaxis
8. Oral anticandidal prophylaxis in patients undergoing chemotherapy for acute leukemia
9. Nystatin prophylaxis in leukemia and lymphoma
10. Candida infections in patients with acute leukemia: Ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis
11. Chemoprophylaxis of fungal infections
12. Nystatin prophylaxis of fungal colonization and infection in granulocytopenic patients: Correlation of colonization and clinical outcome
13. Antifungal prophylaxis during neutropenia or allogenic bone marrow transplantation: What is the state of the art?
14. Infection in acute leukemia patients receiving oral nonabsorbable antibiotics
15. Protective environment for marrow transplant recipients - A prospective study
16. Prevention of gram-positive and Candida albicans infections using teicoplanin and fluconazole: A randomized study in neutropenic children
17. The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients: The bone marrow transplantation team
18. The effect of fluconazole as prophylaxis for neutropenic patients on the isolation of Candida spp. from surveillance cultures
19. Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients
20. Prophylactic action of oral fluconazole against infection in neutropenic patients - A meta-analysis of 16 randomized, controlled trials
21. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients
22. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients
23. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients
24. Liposomal amphotercin B (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: A randomized, double-blind, placebo-controlled study
25. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: Data of a prematurely stopped clinical trial
26. Meta-analysis in clinical research
27. Meta-analyses of randomized controlled trials
28. Ketoconazole versus intraconazole for antifungal prophylaxis in patients with severe granulocytopenia: Preliminary results of two non-randomized studies
29. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia
30. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based upon purpose and intensity of cytotoxic therapy
31. Antifungal prophylaxis in neutropenic cancer patients: A meta-analysis of randomized controlled trials
32. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
33. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-anlysis?
34. Fixed effects models
35. Random effects models
36. Meta-analysis in clinical trials
37. Bias in metaanalysis detected by a simple, graphical test
38. An assessment of clinically useful measures of the consequences of treatment
39. Fluconazole prophylaxis and Candidafungemia in neutropenic children with malignancies
40. Fluconazole in children: First experience with prophylaxis in chemotherapy-induced neutropenia in pediatric patients with cancer
41. Orointestinal yeast colonization of paediatric oncologic patients during antifungal prophylaxis: Results of quantitative culture and Candida serology and comparison of three polyenes
42. Fluconazole versus amphotericin B for the prevention of fungal infection in neutropenic patients with hematologic malignancy
43. Comparison of oral fluconazole and amphotericin B in the prophylaxis of fungal infection in neutropenic patients treated for acute leukemia
44. Clinical experience in the prevention of candidiasis by nystatin in children with acute lymphocytic leukemia
45. Prophylaxis of oropharyngeal candidiasis with fluconazole
46. Antifungal chemoprophyaxis in cancer children: A prospective randomized controlled study
47. A co-operative study on prophylaxis of fungal infection in patients with hematological diseases: Prophylactic effect of oral administration of amphotericin B
48. Empiric therapy with fluconazole in granulocytopenic patients with carcinoma or leukemia
49. Fluconazole versus nystatin for the prevention of fungal infection in neutropenic children receiving cytotoxic chemotherapy
50. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies: A multicentre study group
51. Fluconazole versus nystatin in the prevention of Candida infections in children and adolescents undergoing remission-induction or consolidation chemotherapy for cancer
52. Low-dose amphotericin B reduces the frequency of invasive Aspergillus infections in allogeneic marrow transplantation
53. Prophylaxis of fungal infections with itraconazole during remission-induction therapy
54. Safety and efficacy of itraconazole in prevention of fungal infections in neutropenic patients
55. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole
56. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation
57. Oral itraconazole plus nasal amphotericin B for prophylaxis of invasive aspergillosis in patients with haematological malignancies
58. Efficacy of antifungal prophylaxis in bone marrow transplantation
59. Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies
60. Prophylaxis of candidiasis in patients with leukemia and bone marrow transplants
61. Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients
62. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation
63. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukemia
64. A randomised controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies
65. Ketoconazole versus nystatin as prophylaxis against fungal infection for lymphoma patients receiving chemotherapy
66. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation
67. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial
68. Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients
69. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias
70. Prophylactic use of fluconazole in neutropenic cancer patients
71. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - A prospective, randomized, double-blind study
72. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia
73. Effect of itraconazole in the prevention of fungal infections among neutropenic patients with hematological malignancies and intensive chemotherapy. A double blind placebo controlled study
74. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial
75. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients
76. Prevention of mycosis in granulocytopenic patients with prophylactic ketoconazole treatment
77. Infection prophylaxis in acute leukemia. Comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole, and a combination of the two
78. A randomized trial comparing ketoconazole and nystatin prophylactic therapy in neutropenic patients
79. Ketoconazole in the prevention of candidiasis in patients with cancer. A prospective, randomized, controlled, double-blind study
80. Does ketoconazole prevent fungal infection in children treated with high dose chemotherapy and bone marrow transplantation? Results of a randomized placebo controlled trial
81. Oral ketoconazole for Candida infections during induction therapy for acute leukemia in adults: More bacteremias
82. Prophylactic treatment with miconazole in patients highly predisposed to fungal infection - A placebo-controlled double blind study
83. Prevention of fungal sepsis in patients with prolonged neutropenia: A randomized, double-blind, placebo-controlled trial of intravenous miconazole
84. Management of fungal infection in neutropenic patients with fluconazole
85. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukemia
86. Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy-induced neutropenic patients with haematological malignancies
87. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia
88. Preventing fungal infection in neutropenic patients with acute leukemia: Fluconazole compared with oral amphotericin
89. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients
90. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B
91. Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients
92. Prophylaxis of fungal infections in neutropenic patients. An open, randomized, comparative trial of the efficacy and safety of itraconazole oral solution versus a combination of oral amphotericin B and nystatin
93. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: A randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B
94. Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients
95. Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia
96. Efficacy of ketoconazole versus nystatin in prevention of fungal infections in neutropenic patients
97. Comparative trial of ketoconazole and nystatin for the prevention of fungal infection in neutropenic patients treated in a protective environment
98. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebocontrolled trial
99. Catheter-related complications of cancer therapy
100. Predictors of adverse outcome in cancer patients with candidemia
101. Invasive aspergillosis in acute leukemia: Correlation with nose cultures and antibiotic use
102. Prolonged granulocytopenia: The major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia
103. Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia
104. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients
105. Imact of air filtration on nosocomial aspergillus infections. Unique risk of bone marrow transplant recipients
106. Importance of Candida species other than C. albicans as pathogens in oncology patients
107. Antifungal prophylaxis in patients with hematological malignancies: A reappraisal
108. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole
109. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial
110. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever
111. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
112. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients - Recommendations of CDC, the Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplantation
113. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease
114. Chronic graft-versushost disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study
115. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation
116. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies
117. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Société Française de Greffe de Moelle
118. A Canadian randomized study comparing peripheral blood (PB) and bone marrow (BM) in patients undergoing matched sibling transplants for acute myeloid malignancies
119. Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukemia